BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Prostate cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for prostate cancer: 431 (223 sponsors; 62 newly posted in the last 180 days, 14 stopped in the last 180 days; 24 new-entrant sponsors). Momentum score 12.5, rank 54 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 3, Phase 1 132, Phase 2 140, Phase 3 70, Phase 4 6, N/A 80.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN27P3 8, NA 7, P4 1, P2 10, P1 133
Janssen Research & Development, LLC21P1 11, P3 7, P2 335
Pfizer PFE11P3 6, P2 2, P1 1, NA 211
Novartis Pharmaceuticals NVS31P3 4, P2 12, NA 9, P1 5, P4 145
Aragon Pharmaceuticals, Inc.6P1 2, P3 401
Jiangsu HengRui Medicine Co., Ltd.12P1 4, P3 3, P2 514
Merck Sharp & Dohme LLC MRK7P3 3, P2 410
Norroy Bioscience Co., LTD4P3 3, P2 130
FutureChem3P3 310
Amgen AMGN7P3 2, P1 502
Eli Lilly and Company LLY7P1 5, P3 202
Exelixis EXEL6P3 2, P1 412
Clarity Pharmaceuticals Ltd3P2 1, P3 201
Hinova Pharmaceuticals Inc.3P3 2, P2 110
Curium US LLC2P3 200
Telix Pharmaceuticals (Innovations) Pty Limited TLX2P3 201
Bayer16P1 2, NA 10, P3 1, P4 2, P2 122
GlaxoSmithKline4P2 2, P1 1, P3 110
Qilu Pharmaceutical Co., Ltd.4P1 1, P2 2, P3 121
Candel Therapeutics, Inc. CADL3P2 2, P3 101
Five Eleven Pharma, Inc.2P3 1, P2 100
Lantheus Medical Imaging LNTH2P3 1, NA 110
ORIC Pharmaceuticals ORIC2P3 1, P1 110
ABX advanced biochemical compounds GmbH1P3 101
Astellas (Beijing) Pharmaceutical R&D Co., Ltd.1P3 100

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-24 est.P1/P2AstraZeneca AZNNCT06267729 Study of AZD0754 in Participants With Metastatic Prostate CancerMetastatic Prostate Cancerrecruiting60
2026-11-30 est.P1/P2OncoC4, Inc.NCT05682443 ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPCMetastatic Castration-resistant Prostate Canceractive not recruiting148
2026-12 est.P1/P2Sapience TherapeuticsNCT04478279 A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsGlioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brainactive not recruiting125
2026-12 est.P2Zenith EpigeneticsNCT04986423 ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate Cancerrecruiting200
2026-12 est.P1/P2Monte Rosa Therapeutics, Inc GLUENCT05546268 Study of Oral MRT-2359 in Selected Cancer PatientsNSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC active not recruiting174
2026-12 est.P1/P2Bivision Pharmaceuticals, Inc.NCT06139575 Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate CancerProstate Cancerrecruiting90
2026-12 est.P1/P2858 Therapeutics, Inc.NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesAdvanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovarrecruiting120
2026-12 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT06568094 A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate CancerProstate Cancerrecruiting100
2026-12 est.P2Jina Pharmaceuticals Inc.NCT06890832 A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate CancerMetastatic Castration-resistant Prostate Cancer, MCRPCnot yet recruiting75
2026-12 est.P1/P2Qilu Pharmaceutical Co., Ltd.NCT07198633 A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate CancerAdvanced Prostate Cancerrecruiting212
2026-12-01 est.P3Janssen Research & Development, LLCNCT03767244 A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyProstatic Neoplasmsactive not recruiting2517
2026-12-03 est.P2Novartis Pharmaceuticals NVSNCT06991556 An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Metastatic Hormone-sensitive Prostate Canceractive not recruiting168
2026-12-15 est.P1/P2PMV Pharmaceuticals, Inc PMVPNCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Crecruiting300
2026-12-23 est.P2Novartis Pharmaceuticals NVSNCT05849298 A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCProstatic Neoplasmactive not recruiting49
2026-12-23 est.P2Fusion Pharmaceuticals Inc. HTOONCT06402331 FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Castration-resistant Prostate Canceractive not recruiting110
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT04691804 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus PlacebMetastatic Castration-Resistant Prostate Cancer (mCRPC)active not recruiting496
2026-12-31 est.P3Clarity Pharmaceuticals LtdNCT06970847 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate CancerProstate Cancer; Prostate Cancer Patients With Detectable PSA Following Prostatectomy; Prostate Cancactive not recruiting220
2027-01 est.P3Telix Pharmaceuticals (Innovations) Pty Limited TLXNCT07052214 PSMA PET Combined With MRI for the Detection of PCaPCA; Prostate Cancer; Prostatic Neoplasm; PSMA PET; Diagnostic Imaging; Elevated PSA; Positron Emissactive not recruiting338
2027-01-01 est.P1/P2Second Life TherapeuticsNCT07341737 SL-28 for Advanced Solid TumoursHead & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cancerecruiting60
2027-01-30 est.P2CurasightNCT06474806 Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate CancerProstate Cancerrecruiting168
2027-02 est.P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT06241846 A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPCMetastatic Castration-resistant Prostate Cancer (mCRPC)recruiting100
2027-02 est.P2Candel Therapeutics, Inc. CADLNCT07332000 A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecProstate Cancer Patients Treated by Radiotherapy; Prostate Cancer (Adenocarcinoma)recruiting45
2027-02-02 est.P2Cellvax Therapeutics IncNCT06636682 FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate CancerProstate Cancer (Adenocarcinoma); Prostate CA; Prostate Cancers; Prostate Cancer (Post Prostatectomyrecruiting100

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-18 est.P2/P3Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairNCT03348670 Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide PolymorphismsProstate Canceractive not recruiting600
2026-11-17 est.P2Novartis Pharmaceuticals NVSNCT06894511 An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPCMetastatic Castration Resistant Prostate Cancer (mCRPC)active not recruiting7
2026-11-06 est.P2Novartis Pharmaceuticals NVSNCT06004661 Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionMetastatic Castration-Resistant Prostate Cancer (mCRPC)active not recruiting23
2026-11-05 est.P1/P2AstraZeneca AZNNCT07336446 A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer DrugsProstate Canceractive not recruiting6
2026-11 est.P1/P2TYK Medicines, IncNCT07104643 Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)mCRPCnot yet recruiting48
2026-10-31 est.P1/P2Orion Corporation, Orion Pharma ORNNCT03436485 Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate CancerProstate Cancer Metastaticactive not recruiting204
2026-10-30 est.P1/P2Antelope Surgical Solutions, IncNCT06906471 A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NSProstate Cancer; Prostate Cancer (Adenocarcinoma); Fluorescence Imagingactive not recruiting15
2026-10-19P1/P2Arsenal Biosciences, Inc.NCT07285694 AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)Metastatic Castration Resistant Prostate Cancer (mCRPC)terminated3
2026-10-12 est.P3Janssen Research & Development, LLCNCT05884398 A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPCMetastatic Castrate-sensitive Prostate Canceractive not recruiting420
2026-10 est.P1/P2TYK Medicines, IncNCT07104617 Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)Metastatic Castration-resistant Prostate Cancer (mCRPC)not yet recruiting48
2026-10 est.P3Curium US LLCNCT06235151 Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate CancerProstate Cancer; Prostate Adenocarcinomaactive not recruiting439
2026-09 est.P3Clarity Pharmaceuticals LtdNCT06056830 Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical ProstatectomyProstate Cancer; Prostatic Neoplasmsrecruiting383
2026-09 est.P1/P2Clarity Pharmaceuticals LtdNCT04868604 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)Prostatic Neoplasms, Castration-Resistantrecruiting54
2026-08-27 est.P1/P2Blue Earth Therapeutics LtdNCT05413850 Anti-tumour Activity of (177Lu) rhPSMA-10.1 InjectionProstate Cancer; Metastatic Castration-resistant Prostate Cancer; mCRPC; Urogenital Neoplasms; Prostrecruiting82
2026-08 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT07056439 Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer PatientsPET Imaging in Patients With Prostate Cancernot yet recruiting50
2026-08 est.P1/P2AtlasMedx, IncorporatedNCT04503265 A Trial of AMXI-5001 for Treatment in Patients With Advanced MalignanciesAdvanced Malignant Neoplasm; Breast Cancer; Ovarian Cancer; Homologous Recombination Deficiency; Prorecruiting122
2026-06-24P2Debiopharm International SANCT06395753 A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate CancerProstate Cancercompleted55
2026-06-11P3HTA Co., Ltd.NCT06754085 Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate CancerProstate Cancercompleted131
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "prostate cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.